We have some exciting news to share! The Motley Fool UK has now become an independent, UK-owned company, led by our long-serving UK management team — Mark Rogers, Chris Nials and Heather Adlington. In practical terms, it’s the same team you know, now fully focused on serving our UK readers and members.

Just as importantly, our approach remains unchanged: long-term, jargon-free, and on your side. We’ll be introducing a new name and brand over the coming weeks — we're very excited to share it with you and embark on this new chapter together!

3 potentially overvalued FTSE stocks I’d still consider buying on a dip

Some recent stock market successes for UK companies have resulted in over-inflated stock prices. I look at three worth watching in 2020.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

While worldwide worries have prevented many stocks from thriving in 2019, a select few have defied expectations and done extremely well. Positive sentiment drives buyers to these stocks, but it can also result in them becoming overvalued, when they become too expensive for their own good.

I think this is the case for several such successes in recent months, but there are still a few I’d take my chances with, particularly if the share price drops.

From the FTSE 100, I’d choose global pharmaceutical giant Astrazeneca (LSE:AZN), while from the FTSE 250, I’d choose Future (LSE:FUTR), an international media group and digital publisher, and JD Sports Fashion, the sports retailer.

Health for wealth

Astrazeneca has had an exceptionally good year. Its share price has risen over 27% since January.  This is thanks to several positive developments in its drug research and commercialisation.

It specialises in the treatment of diseases in the areas of oncology, cardiovascular, renal and metabolism, and respiratory.

November alone was impressive. Its drug Imfinzi was granted FDA Priority Review for the treatment of patients with extensive-stage small cell lung cancer, an aggressive, fast-growing form of lung cancer. Calquence, a leukaemia drug, was approved in the US for adult patients, Qtrilmet was approved in the EU for the treatment of type-2 diabetes, and the FDA accepted a New Drug Application and granted Priority Review for Selumetinib, as a potential new medicine for paediatric patients with NF1, a rare and incurable genetic condition.

This pharma favourite has a trailing price-to-earnings ratio (P/E) of 47 and its dividend yield is 2.9%. Earnings per share are £1.31 and its debt ratio is 68%.

Future returns

Customer loyalty has contributed to record revenue growth for Future and according to the London Stock Exchange, its e-commerce clicks soared 44% year-on-year following Black Friday 2019.

This publishing giant’s top online properties include technology sites TechRadar, GamesRadar, and Tom’s Guide. Leading products advertised and sold through these sites on Black Friday included Google’s Pixel 4 smartphone, and the Sony Playstation VR, as well as subscriptions to streaming services such as Hulu and Disney+.

The relevance and trusted nature of these sites give consumers the confidence to shop online as the sites offer expert buying advice across consumer categories such as tech, games, music, homes, and more.

Future has recently announced two major acquisitions; a £140m acquisition of TI Media, a UK-based print-let consumer magazine and digital publisher with brands such as Marie Claire and World Soccer. This preceded the £23.5m acquisition of Barcroft Studios, creator of digital video and television content.

Future has an astronomical trailing P/E of 138. Its dividend yield is a very low 0.14% but the cover is more than 10 times. Earnings per share are 9p and its debt ratio is a low 12%.

Sporting hero

JD Sports Fashion has a P/E of 28, so not as high as the previous two. Its dividend yield is a very low 0.22% but it has a dividend cover of 15 times, which means it could increase if the company continues to thrive. Earnings per share are 26p.

It’s important to note that these stocks are currently overvalued, so I think they’re worth watching for the possibility to buy on a dip, but I wouldn’t rush out and buy them at today’s prices.

Kirsteen has no position in any of the shares mentioned. The Motley Fool UK has recommended AstraZeneca. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investor looking at stock graph on a tablet with their finger hovering over the Buy button
Investing Articles

Am I crazy to consider this risky FTSE 100 bank stock over Rolls-Royce shares?

Mark Hartley weighs up the pros and cons of investing in a FTSE 100 growth stock that’s giving Rolls-Royce shares…

Read more »

Road 2025 to 2032 new year direction concept
Investing Articles

How did HSBC pay more passive income via dividends in 2025 than any other British company?

Despite only an average yield, HSBC was the UK's passive income hero of 2025, paying out more in dividends than…

Read more »

The flag of the United States of America flying in front of the Capitol building
Investing Articles

1 S&P 500 name I can’t stop buying in my Stocks and Shares ISA

S&P 500 software companies have been falling out of the sky. But Stephen Wright's been focusing on one in particular…

Read more »

Young brown woman delighted with what she sees on her screen
Investing Articles

Analysts reckon the Lloyds share price should be 21% higher!

James Beard’s been looking at the latest Lloyds Banking Group share price forecasts. But is the bank’s stock really worth…

Read more »

Investing Articles

How much time and money would it take to become a stock market millionaire?

Is it realistic to aim for a million by investing a few hundred pounds a week in the stock market?…

Read more »

Fans of Warren Buffett taking his photo
Investing Articles

Want to start buying shares? How good are you at these 3 things?

This trio of simple questions can help provide some food for thought to anyone who wonders whether they are ready…

Read more »

Three generation family are playing football together in a field. There are two boys, their father and their grandfather.
Investing Articles

How to target a £1,183 monthly passive income in a SIPP for life!

Own a Self-Invested Personal Pension (SIPP)? Here's how you could maximise your chances of a comfortable retirement by buying dividend…

Read more »

Affectionate Asian senior mother and daughter using smartphone together at home, smiling joyfully
Investing Articles

What are the best shares to buy to earn £1m or more in an ISA?

Searching for the best ISA stocks to buy to target a million? Royston Wild discusses the key things to look…

Read more »